DK3069720T3 - Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme - Google Patents
Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme Download PDFInfo
- Publication number
- DK3069720T3 DK3069720T3 DK14861410T DK14861410T DK3069720T3 DK 3069720 T3 DK3069720 T3 DK 3069720T3 DK 14861410 T DK14861410 T DK 14861410T DK 14861410 T DK14861410 T DK 14861410T DK 3069720 T3 DK3069720 T3 DK 3069720T3
- Authority
- DK
- Denmark
- Prior art keywords
- eosinophylic
- diseases
- treatment
- application
- composition containing
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008196 pharmacological composition Substances 0.000 title 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013150861/15A RU2552929C1 (ru) | 2013-11-14 | 2013-11-14 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| PCT/RU2014/000855 WO2015072893A1 (ru) | 2013-11-14 | 2014-11-12 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3069720T3 true DK3069720T3 (da) | 2019-11-25 |
Family
ID=53057723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14861410T DK3069720T3 (da) | 2013-11-14 | 2014-11-12 | Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9949962B2 (enExample) |
| EP (2) | EP3466425B1 (enExample) |
| JP (4) | JP2016540749A (enExample) |
| KR (2) | KR102312013B1 (enExample) |
| CN (2) | CN110200968A (enExample) |
| AU (2) | AU2014349246C1 (enExample) |
| BR (1) | BR112016010515B1 (enExample) |
| CA (1) | CA2930231C (enExample) |
| CY (1) | CY1122500T1 (enExample) |
| DK (1) | DK3069720T3 (enExample) |
| EA (4) | EA032940B1 (enExample) |
| ES (2) | ES2836887T3 (enExample) |
| HU (1) | HUE046671T2 (enExample) |
| IL (2) | IL245429B (enExample) |
| LT (1) | LT3069720T (enExample) |
| MX (2) | MX386887B (enExample) |
| PL (2) | PL3069720T3 (enExample) |
| PT (1) | PT3069720T (enExample) |
| RU (1) | RU2552929C1 (enExample) |
| SG (1) | SG10201900504XA (enExample) |
| SI (1) | SI3069720T1 (enExample) |
| UA (1) | UA118687C2 (enExample) |
| WO (1) | WO2015072893A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MX380619B (es) * | 2013-04-12 | 2025-03-12 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| US10370449B2 (en) | 2014-02-28 | 2019-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
| HUE067888T2 (hu) | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | 王晓旭 | 一种治疗高血脂症的药物 |
| CN111093661B (zh) * | 2017-09-07 | 2023-10-27 | 化学免疫疗法有限责任公司 | 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途 |
| RU2712281C1 (ru) * | 2018-11-23 | 2020-01-28 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| SG11202113310UA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| WO2021207367A1 (en) * | 2020-04-07 | 2021-10-14 | Hofseth Biocare Asa | Respiratory treatments using salmonid oil compositions |
| CN115803026A (zh) * | 2020-06-26 | 2023-03-14 | 瓦伦塔有限责任公司 | 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途 |
| WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | Владимир Евгеньевич НЕБОЛЬСИН | Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196767A (ja) | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | ヒドロキサム酸誘導体 |
| AU9134191A (en) | 1990-12-24 | 1992-07-22 | Merrell Dow Pharmaceuticals Inc. | Use of certain glutarimide derivatives in the treatment of depression and mania |
| AU6702894A (en) * | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| CA2466492A1 (en) | 2001-11-07 | 2003-05-15 | Cytos Biotechnology Ag | Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases |
| EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| WO2007007054A1 (en) | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| CN101848732B (zh) | 2007-05-14 | 2013-06-05 | 米迪缪尼有限公司 | 降低嗜酸性粒细胞水平的方法 |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| MX380619B (es) | 2013-04-12 | 2025-03-12 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
-
2013
- 2013-11-14 RU RU2013150861/15A patent/RU2552929C1/ru active
-
2014
- 2014-11-12 HU HUE14861410A patent/HUE046671T2/hu unknown
- 2014-11-12 LT LTEP14861410.0T patent/LT3069720T/lt unknown
- 2014-11-12 EP EP18206980.7A patent/EP3466425B1/en active Active
- 2014-11-12 CA CA2930231A patent/CA2930231C/en active Active
- 2014-11-12 PL PL14861410T patent/PL3069720T3/pl unknown
- 2014-11-12 EP EP14861410.0A patent/EP3069720B1/en active Active
- 2014-11-12 EA EA201891261A patent/EA032940B1/ru not_active IP Right Cessation
- 2014-11-12 ES ES18206980T patent/ES2836887T3/es active Active
- 2014-11-12 WO PCT/RU2014/000855 patent/WO2015072893A1/ru not_active Ceased
- 2014-11-12 SG SG10201900504XA patent/SG10201900504XA/en unknown
- 2014-11-12 AU AU2014349246A patent/AU2014349246C1/en not_active Ceased
- 2014-11-12 PT PT148614100T patent/PT3069720T/pt unknown
- 2014-11-12 PL PL18206980T patent/PL3466425T3/pl unknown
- 2014-11-12 ES ES14861410T patent/ES2759530T3/es active Active
- 2014-11-12 CN CN201910373584.XA patent/CN110200968A/zh active Pending
- 2014-11-12 SI SI201431407T patent/SI3069720T1/sl unknown
- 2014-11-12 JP JP2016530898A patent/JP2016540749A/ja not_active Ceased
- 2014-11-12 MX MX2019006881A patent/MX386887B/es unknown
- 2014-11-12 EA EA201990529A patent/EA037447B1/ru unknown
- 2014-11-12 EA EA201891262A patent/EA032955B3/ru not_active IP Right Cessation
- 2014-11-12 KR KR1020207013125A patent/KR102312013B1/ko not_active Expired - Fee Related
- 2014-11-12 US US15/036,603 patent/US9949962B2/en active Active
- 2014-11-12 BR BR112016010515-0A patent/BR112016010515B1/pt not_active IP Right Cessation
- 2014-11-12 KR KR1020167013675A patent/KR102312294B1/ko not_active Expired - Fee Related
- 2014-11-12 EA EA201690798A patent/EA030961B1/ru not_active IP Right Cessation
- 2014-11-12 CN CN201480062492.5A patent/CN105722511B/zh not_active Expired - Fee Related
- 2014-11-12 DK DK14861410T patent/DK3069720T3/da active
- 2014-11-12 MX MX2016006330A patent/MX365781B/es active IP Right Grant
- 2014-12-11 UA UAA201606370A patent/UA118687C2/uk unknown
-
2016
- 2016-05-01 IL IL245429A patent/IL245429B/en active IP Right Grant
-
2017
- 2017-12-18 US US15/844,703 patent/US10220029B2/en active Active
-
2018
- 2018-10-30 JP JP2018203599A patent/JP6589251B2/ja active Active
- 2018-11-15 AU AU2018264084A patent/AU2018264084C1/en not_active Ceased
-
2019
- 2019-08-21 JP JP2019151258A patent/JP2020002152A/ja not_active Ceased
- 2019-08-21 JP JP2019151253A patent/JP6758677B2/ja not_active Expired - Fee Related
- 2019-11-19 CY CY20191101215T patent/CY1122500T1/el unknown
- 2019-12-11 IL IL271352A patent/IL271352B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3069720T3 (da) | Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme | |
| DK3269716T3 (da) | Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser | |
| DK3317286T3 (da) | Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b | |
| DK3121164T3 (da) | Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK3068392T3 (da) | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme | |
| DK3052485T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| PT3030262T (pt) | Composição farmacêutica de associação | |
| DK3685848T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| DK2968173T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
| DK2967049T3 (da) | Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3049056T3 (da) | Topisk antisvampesammensætning og fremgangsmåder til behandling | |
| DK2968221T3 (da) | Farmaceutisk sammensætning af s-ketaminhydrochlorid | |
| DK3035849T3 (da) | Lægemiddeleluering til beskyttelse in vivo af biosensor-analysander | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK3025586T3 (da) | Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf | |
| DK2903967T6 (da) | Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK3067355T3 (da) | Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat | |
| DK3388427T3 (da) | Derivater af dolastatin 10 og auristatiner | |
| DK2968470T3 (da) | Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme |